Diamyd proceeds with Phase III trial
Av
Diamyd Medical has announced details for its Phase III clinical trial in type-1 diabetes with its lead candidate Diamyd. It plans a Phase III trial in the US and a second Phase III trial which will run in parallel in Europe. It will take around nine months to recruit the 600 patients at the 30 chosen sites across Europe and the US.